Development of a Vaccine Against Pandemic Influenza Viruses: Current Status and Perspectives

REFERENCES

• Treanor J. J., King J. C., Zangwill K. M. New approaches to influenza vaccine. New Generation Vaccines, M. Levine, J. B. Kaper, R. Rappuoli, M. A. Liu, M. F. Good. Marcel Dekker, New York, Basel 2004; 537–558
   Google Scholar
• Claas E. C. J., Osterhaus A. D. M. E., van Beek R., De Jong J. C., Rimmelzwaan G. F., Senne D. A., Krauss S., Shortridge K. F., Webster R. G. Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus. Lancet 1998; 351: 472–477
   PubMed Web of Science ®Google Scholar
• Katz J. M., Bridges C. B., Rowe T., Hu-Primmer J., Lu X., Abernathy R. A., Clarke M., Conn L., Kwong H., Lee M., Au G., Ho Y. Y., Mak K. H., Cox N. J., Fukuda K. Antibody response in individuals infected with avian influenza A (H5N1) viruses and detection of anti-H5 antibody among household and social contacts. J Infect Dis 1999; 180: 1763–1770
   PubMedGoogle Scholar
• Fukuda K., Levandowski R. A., Bridges C. B., Cox N. J. Inactivated Influenza Vaccines. Vaccines, S. A. Plotkin, W. A. Orenstein. Elsevier, Philadelphia 2004; 339–370
   Google Scholar
• Smith G. J., Fan X. H., Wang J., Li K. S., Qin K., Zhang J. X., Vijaykrishna D., Cheung C. L., Huang K., Rayner J. M., Peiris J. S., Chen H., Webster R. G., Guan Y. Emergence and predominance of an H5N1 influenza variant in China. Proc. Natl. Acad. Sci. USA 2006; 103: 16936–16941
   PubMed Web of Science ®Google Scholar
• Palese P. Making better influenza virus vaccines?. Emerg Infect Dis 2006; 12: 61–65
   PubMed Web of Science ®Google Scholar
• Johansson B. E., Brett I. C. Changing perspective on immunization against influenza. Vaccine 2007; 25: 3062–3065
   PubMed Web of Science ®Google Scholar
• Hoskins T. W., Davies J. R., Smith A. J., Miller C. L., Allchin A. Assessment of inactivated influenza A vaccine after three outbreaks of influenza at Christ's Hospital. Lancet 1979; 1: 33–35
   PubMed Web of Science ®Google Scholar
• Treanor J. J., Wilkinson B. E., Masseoud F., Hu-Primmer J., Battaglia R., O'Brien D., Wolff M., Rabinovich G., Blackwelder W., Katz J. M. Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans. Vaccine 2001; 19: 1732–1737
   PubMed Web of Science ®Google Scholar
• Nicholson K. G., Colegate A. E., Podda A., Stephenson I., Wood J., Ypma E., Zambon M. C. Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza. Lancet 2001; 357: 1937–43
   PubMed Web of Science ®Google Scholar
• The World Health Organization Global Influenza Program Surveillance Network. Evolution of H5N1 avian influenza viruses in Asia. Emerg Infect Dis 2005; 11: 1515–1521
   Web of Science ®Google Scholar
• Senne D. A., Panigrahy B., Kawaoka Y., Pearson J. E., Süss J., Lipkind M., Kida H., Webster R. G. Survey of the hemagglutinin (HA) cleavage site sequence of H5 and H7 avian influenza viruses: amino acid sequence at the HA cleavage site as a marker of pathogenicity potential. Avian Dis 1996; 40: 425–437
   PubMed Web of Science ®Google Scholar
• Treanor J. J., Campbell J. D., Zangwill K. M., Rowe T., Wolff M. Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. N Engl J Med 2006; 354: 1343–1351
   PubMed Web of Science ®Google Scholar
• Lin J., Zhang J., Dong X., Fang H., Chen J., Su N., Gao Q., Zhang Z., Liu Y., Wang Z., Yang M., Sun R., Li C., Lin S., Ji M., Liu Y., Wang X., Wood J., Feng Z., Wang Y., Yin W. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 2006; 368: 991–997
   PubMed Web of Science ®Google Scholar
• Zangwill K. M., Treanor J. J., Campbell J. D., Noah D. L., Ryea J. Evaluation of the safety and immunogenicity of a booster (third) dose of inactivated subvirion H5N1 influenza vaccine in humans. J Infect Dis 2008; 197: 580–583
   PubMed Web of Science ®Google Scholar
• Poland G. A., Jacobson R. M., Targonski P. V. Avian and pandemic influenza: an overview. Vaccine 2007; 25: 3057–3061
   PubMed Web of Science ®Google Scholar
• Stephenson I., Gust I., Pervikov Y., Kieny M. P. Development of vaccines against influenza H5. Lancet Infect Dis 2006; 6: 458–460
   PubMed Web of Science ®Google Scholar
• Leroux-Roels I., Borkowski A., Vanwolleghem T., Dramé M., Clement F., Hons E., Devaster J. M., Leroux-Roels G. Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial. Lancet 2007; 370: 580–589
   PubMed Web of Science ®Google Scholar
• Luke C. J., Subbarao K. Vaccines for pandemic influenza. Emerg Infect Dis 2006; 12: 66–72
   PubMed Web of Science ®Google Scholar
• Nichol K. L., Treanor J. J. Vaccines for seasonal and pandemic influenza. J Infect Dis 2006; 194: S111–S118
   PubMed Web of Science ®Google Scholar
• Bresson J. L. P. C., Launay O., Gerdil C., Saville M., Wood J., Höschler K., Zambon M. C. Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial. Lancet 2006; 367: 1657–1664
   PubMed Web of Science ®Google Scholar
• Ninomiya A., Imai M., Tashiro M., Odagiri T. Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model. Vaccine 2007; 25: 3554–3560
   PubMed Web of Science ®Google Scholar
• Bungener L., Geeraedts F., Ter W., Veer Medema J., Wilschut J., Huckriede A. Alum boosts TH2-type antibody responses to whole-inactivated virus influenza vaccine in mice but does not confer superior protection. Vaccine 2008; 26: 2350–2359
   PubMed Web of Science ®Google Scholar
• O'Hagan D. T., Wack A., Podda A. MF59 is a safe and potent vaccine adjuvant for flu vaccines in humans: what did we learn during its development?. Clin. Pharmacol Ther 2007; 82: 740–744
   PubMed Web of Science ®Google Scholar
• Huckriede A., Bungener L., Stegmann T., Daemen T., Medema J., Palache A. M., Wilschut J. The virosome concept for influenza vaccines. Vaccine 2005; 23: S26–S38
   PubMed Web of Science ®Google Scholar
• Glück R., Burri K. G., Metcalfe I. Adjuvant and antigen delivery properties of virosomes. Curr Drug Deliv 2005; 2: 395–400
   PubMedGoogle Scholar
• De Donato S., Granoff D., Minutello M., Lecchi G., Faccini M., Agnello M., Senatore F., Verweij P., Fritzell B., Podda A. Safety and immunogenicity of MF59-adjuvanted influenza vaccine in the elderly. Vaccine 1999; 17: 3094–3101
   PubMed Web of Science ®Google Scholar
• Del Giudice G., Hilbert A. K., Bugarini R., Minutello A., Popova O., Toneatto D., Schoendorf I., Borkowski A., Rappuoli R., Podda A. An MF59-adjuvanted inactivated influenza vaccine containing A/Panama/1999 (H3N2) induced broader serological protection against heterovariant influenza virus strain A/Fujian/2002 than a subunit and a split influenza vaccine. Vaccine 2006; 24: 3063–3065
   PubMed Web of Science ®Google Scholar
• Stephenson I., Bugarini R., Nicholson K. G., Podda A., Wood J. M., Zambon M. C., Katz J. M. Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy. J Infect Dis 2005; 191: 1210–1215
   PubMed Web of Science ®Google Scholar
• Ansaldi F., Bacilieri S., Durando P., Sticchi L., Valle L., Montomoli E., Icardi G., Gasparini R., Crovari P. Cross-protection by MF59-adjuvanted influenza vaccine: neutralizing and haemagglutination-inhibiting antibody activity against A(H3N2) drifted influenza viruses. Vaccine 2008; 26: 1525–1529
   PubMed Web of Science ®Google Scholar
• Wack A., Baudner B. C., Hilbert A. K., Manini I., Nuti S., Tavarini S., Scheffczik H., Ugozzoli M., Singh M., Kazzaz J., Montomoli E., Del Giudice G., Rappuoli R., O'Hagan D. T. Combination adjuvants for the induction of potent, long-lasting antibody and T-cell responses to influenza vaccine in mice. Vaccine 2008; 26: 552–561
   PubMed Web of Science ®Google Scholar
• de Bruijn I., Meyer I., Gerez L., Nauta J., Giezeman K., Palache B. Antibody induction by virosomal, MF59-adjuvanted, or conventional influenza vaccines in the elderly. Vaccine 2007; 26: 119–127
   PubMed Web of Science ®Google Scholar
• de Bruijn I. A., Nauta J., Gerez L., Palache A. M. The virosomal influenza vaccine Invivac: immunogenicity and tolerability compared to an adjuvanted influenza vaccine (Fluad) in elderly subjects. Vaccine 2006; 24: 6629–6631
   PubMed Web of Science ®Google Scholar
• Garçon N., Chomez P., Van Mechelen M. GlaxoSmithKline Adjuvant Systems in vaccines: concepts, achievements and perspectives. Expert Rev. Vaccines 2007; 6: 723–739
   Google Scholar
• Leroux-Roels I., Bernhard R., Gérard P., Dramé M., Hanon E., Leroux-Roels G. Broad Clade 2 cross-reactive immunity induced by an adjuvanted clade 1 rH5N1 pandemic influenza vaccine. PLoS ONE. 2008; 3: e1665
   PubMed Web of Science ®Google Scholar
• Vandepapelière P., Horsmans Y., Moris P., Van Mechelen M., Janssens M., Koutsoukos M., Van P., Belle Clement F., Hanon E., Wettendorff M., Garçon N., Leroux-Roels G. Vaccine adjuvant systems containing monophosphoryl lipid A and QS21 induce strong and persistent humoral and T cell responses against hepatitis B surface antigen in healthy adult volunteers. Vaccine 2008; 26: 1375–1386
   PubMed Web of Science ®Google Scholar
• Stephenson I., Zambon M. C., Rudin A., Colegate A., Podda A., Bugarini R., Del G., Giudice Minutello A., Bonnington S., Holmgren J., Mills K. H., Nicholson K. G. Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers. J Virol 2006; 80: 4962–4970
   PubMed Web of Science ®Google Scholar
• Treanor J., Nolan C., O'Brien D., Burt D., Lowell G., Linden J., Fries L. Intranasal administration of a proteosome-influenza vaccine is well-tolerated and induces serum and nasal secretion influenza antibodies in healthy human subjects. Vaccine 2006; 24: 254–262
   PubMed Web of Science ®Google Scholar
• Lowell G. H. B. D., White G. Proteosome technology for vaccines and adjuvants. New Generation Vaccines, M. M. Levine, J. B. Kaper, R. Rappuoli, M. A. Liu, M. F. Good. Marcel Dekker, New York - Basel 2004; 271–283
   Google Scholar
• Morein B., Sundquist B., Höglund S., Dalsgaard K., Osterhaus A. Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses. Nature 1984; 308: 457–460
   PubMed Web of Science ®Google Scholar
• Rimmelzwaan G. F., Baars M., van Beek R., van G., Amerongen Lövgren-Bengtsson K., Claas E. C., Osterhaus A. D. Induction of protective immunity against influenza virus in a macaque model: comparison of conventional and iscom vaccines. J Gen Virol 1997; 78: 757–765
   PubMed Web of Science ®Google Scholar
• Rimmelzwaan G. F., Claas E. C., van Amerongen G., de Jong J. C., Osterhaus A. D. ISCOM vaccine induced protection against a lethal challenge with a human H5N1 influenza virus. Vaccine 1999; 17: 1355–1358
   PubMed Web of Science ®Google Scholar
• Rimmelzwaan G. F., Baars M., van Amerongen G., van Beek R., Osterhaus A. D. A single dose of an ISCOM influenza vaccine induces long-lasting protective immunity against homologous challenge infection but fails to protect Cynomolgus macaques against distant drift variants of influenza A (H3N2) viruses. Vaccine 2001; 20: 158–163
   PubMed Web of Science ®Google Scholar
• Webster R. G., Govorkova E. A. H5N1 influenza—continuing evolution and spread. N Engl J Med 2006; 335: 2174–2177
   Google Scholar
• Sugaya N., Nerome K., Ishida M., Matsumoto M., Mitamura K., Nirasawa M. Efficacy of inactivated vaccine in preventing antigenically drifted influenza Type A and well-matched Type B. JAMA 1994; 272: 1122–1126
   PubMed Web of Science ®Google Scholar
• Brett I. C., Johansson B. E. Immunization against influenza A virus: comparison of conventional inactivated, live-attenuated and recombinant baculovirus produced purified hemagglutinin and neuraminidase vaccines in a murine model system. Virology 2005; 339: 273–280
   PubMed Web of Science ®Google Scholar
• Besselaar T. G., Botha L., McAnerney J. V., Schoub B. D. Antigenic and molecular analysis of influenza A (H3N2) virus strains isolated from a localised influenza outbreak in South Africa in 2003. J Med Virol 2004; 73: 71–78
   PubMed Web of Science ®Google Scholar
• CDC. Update: Influenza Activity—United States, 2003–2004 season. Morb Mortal Wkly Rep 2004; 53: 284–287
   Google Scholar
• Govorkova E. A., Webby R. J., Humberd J., Seiler J. P., Webster R. G. Immunization with reverse-genetics-produced H5N1 influenza vaccine protects ferrets against homologous and heterologous challenge. J Infect Dis 2006; 194: 159–167
   PubMed Web of Science ®Google Scholar
• Lipatov A. S., Hoffmann E., Salomon R., Yen H. L., Webster R. G. Cross-protectiveness and immunogenicity of influenza A/Duck/Singapore/3/97(H5) vaccines against infection with A/Vietnam/1203/04(H5N1) virus in ferrets. J Infect Dis 2006; 194: 1040–1043
   PubMedGoogle Scholar
• Onishchenko G. G., Zverev V. V., Katlinskii A. V., Semchenko A. V., Korovkin S. A., Mel'nikov S. Ia., Mironov A. N. Tetravaccine–new fundamental approach to prevention of influenza pandemic. Zh Mikrobiol Epidemiol Immunobiol 2007; 4: 15–19
   Google Scholar
• Webby R., Perez D. R., Coleman J. S., Guan Y., Knight J. H., Govorkova E. A., McClain-Moss L. R., Peiris J. S., Rehg J. E., Tuomanen E. I., Webster R. G. Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines. Lancet 2004; 363: 1099–1103
   PubMed Web of Science ®Google Scholar
• Hoffmann E., Lipatov A. S., Webby R. J., Govorkova E. A., Webster R. G. Role of specific hemagglutinin amino acids in the immunogenicity and protection of H5N1 influenza virus vaccines. Proc Natl Acad Sci USA 2005; 102: 12915–12920
   Google Scholar
• Lipatov A. S., Webby R. J., Govorkova E. A., Krauss S., Webster R. G. Efficacy of H5 influenza vaccines produced by reverse genetics in a lethal mouse model. J Infect Dis 2005; 191: 1216–1220
   PubMed Web of Science ®Google Scholar
• Tian G., Zhang S., Li Y., Bu Z., Liu P., Zhou J., Li C., Shi J., Yu K., Chen H. Protective efficacy in chickens, geese and ducks of an H5N1-inactivated vaccine developed by reverse genetics. Virology 2005; 341: 153–162
   PubMed Web of Science ®Google Scholar
• Girard M., Cherian T, Pervikov Y., Kieny M. P. A review of vaccine research and development: human acute respiratory infections. Vaccine 2005; 23: 5708–5724
   PubMed Web of Science ®Google Scholar
• Fauci A. S. Pandemic influenza threat and preparedness. Emerg Infect Dis 2006; 12: 73–77
   PubMed Web of Science ®Google Scholar
• Shi H., Liu X. F., Zhang X., Chen S., Sun L., Lu J. Generation of an attenuated H5N1 avian influenza virus vaccine with all eight genes from avian viruses. Vaccine 2007; 25: 7379–7384
   PubMed Web of Science ®Google Scholar
• Cinatl J. J., Michaelis M., Doerr H. W. The threat of avian influenza A (H5N1). Part IV: Development of vaccines. Med Microbiol Immunol 2007; 196: 213–225
   PubMed Web of Science ®Google Scholar
• Treanor J. J., Schiff G. M., Couch R. B., Cate T. R., Brady R. C., Hay C. M., Wolff M., She D., Cox M. M. Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults. J Infect Dis 2006; 193: 1223–1228
   PubMed Web of Science ®Google Scholar
• Wang K., Holtz K. M., Anderson K., Chubet R., Mahmoud W., Cox M. M. Expression and purification of an influenza hemagglutinin—one step closer to a recombinant protein-based influenza vaccine. Vaccine 2006; 24: 2176–2185
   PubMed Web of Science ®Google Scholar
• Galarza J. M., Latham T., Cupo A. Virus-like particle (VLP) vaccine conferred complete protection against a lethal influenza virus challenge. Viral Immunol. 2005; 18: 244–251
   PubMed Web of Science ®Google Scholar
• Bright R. A., Carter D. M., Daniluk S., Toapanta F. R., Ahmad A., Gavrilov V., Massare M., Pushko P., Mytle N., Rowe T., Smith G., Ross T. M. Influenza virus-like particles elicit broader immune responses than whole virion inactivated influenza virus or recombinant hemagglutinin. Vaccine 2007; 25: 3871–3878
   PubMed Web of Science ®Google Scholar
• Galarza J. M., Latham T., Cupo A. Virus-like particle vaccine conferred complete protection against a lethal influenza virus challenge. Viral Immunol 2005; 18: 365–372
   PubMed Web of Science ®Google Scholar
• Matassov D., Cupo A., Galarza J. M. A novel intranasal virus-like particle (VLP) vaccine designed to protect against the pandemic 1918 influenza A virus (H1N1). Viral Immunol 2007; 20: 441–452
   PubMed Web of Science ®Google Scholar
• Pushko P. T. T. M., Bu F., Knell J., Robinson R., Smith G. Influenza virus-like particles comprised of the HA, NA, and M1 proteins of H9N2 influenza virus induce protective immune responses in BALB/c mice. Vaccine 2005; 23: 5751–5759
   PubMed Web of Science ®Google Scholar
• Treanor J. J., Schiff G. M., Hayden F. G., Brady R. C., Hay C. M., Meyer A. L., Holden-Wiltse J., Liang H., Gilbert A., Cox M. Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial. JAMA 2007; 297: 1577–1582
   PubMed Web of Science ®Google Scholar
• Carrat F., Flahault A. Influenza vaccine: the challenge of antigenic drift. Vaccine 2007; 25: 6852–6862
   PubMed Web of Science ®Google Scholar
• Kendal A. P. Cold-adapted live attenuated influenza vaccines developed in Russia: can they contribute to meeting the needs for influenza control in other countries?. Eur J Epidemiol 1997; 13: 591–609
   PubMed Web of Science ®Google Scholar
• Belshe R. B., Edwards K. M., Vesikari T., Black S. V., Walker R. E., Hultquist M., Kemble G., Connor E. M. CAIV-T Comparative Efficacy Study Group. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007; 356: 685–696
   PubMed Web of Science ®Google Scholar
• Belshe R. B., Maassab H. F., Mendelman P. M. Influenza Vaccine- Live. Orenstein, S. A. Vaccines, W. A. Plotkin. Elsevier, Philadelphia 2004; 371–388
   Google Scholar
• Ohmit S. E., Victor J. C., Rotthoff J. R., Teich E. R., Truscon R. K., Baum L. L., Rangarajan B., Newton D. W., Boulton M. L., Monto A. S. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N Engl J Med 2006; 355: 2513–2522
   PubMed Web of Science ®Google Scholar
• Jameson J., Cruz J., Ennis F. A. Human cytotoxic T-lymphocyte repertoire to influenza A viruses. J Virol 1998; 72: 8682–8689
   PubMed Web of Science ®Google Scholar
• Boon A. C., de Mutsert G., van Baarle D., Smith D. J., Lapedes A. S., Fouchier R. A., Sintnicolaas K., Osterhaus A. D., Rimmelzwaan G. F. Recognition of homo- and heterosubtypic variants of influenza A viruses by human CD8+ T lymphocytes. J Immunol 2004; 172: 2453–2460
   PubMed Web of Science ®Google Scholar
• Jameson J., Cruz J., Terajima M., Ennis F. A. Human CD8+ and CD4+ T lymphocyte memory to influenza A viruses of swine and avian species. J Immunol 1999; 162: 7578–7583
   PubMed Web of Science ®Google Scholar
• Seo S. H., Webster R. G. Cross-reactive, cell-mediated immunity and protection of chickens from lethal H5N1 influenza virus infection in Hong Kong poultry markets. J Virol 2001; 75: 2516–2525
   PubMed Web of Science ®Google Scholar
• Li S., Liu C., Klimov A., Subbarao K., Perdue M. L., Mo D., Ji Y., Woods L., Hietala S., Bryant M. Recombinant influenza A virus vaccines for the pathogenic human A/Hong Kong/97 (H5N1) viruses. J Infect Dis 1999; 179: 1132–1138
   PubMed Web of Science ®Google Scholar
• Suguitan A. L., McAuliffe J. J., Mills K. L., Jin H., Duke G., Lu B., Luke C. J., Murphy B., Swayne D. E., Kemble G., Subbarao K. Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS ONE. 2006; 3: e360
   Google Scholar
• Lu X., Edwards L. E., Desheva J. A., Nguyen D. C., Rekstin A., Stephenson I., Szretter K., Cox N. J., Rudenko L. G., Klimov A., Katz J. M. Cross-protective immunity in mice induced by live-attenuated or inactivated vaccines against highly pathogenic influenza A (H5N1) viruses. Vaccine 2006; 24: 6588–6593
   PubMed Web of Science ®Google Scholar
• Desheva J. A., Lu X. H., Rekstin A. R., Rudenko L. G., Swayne D. E., Cox N. J., Katz J. M., Klimov A. I. Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential. Vaccine 2006; 24: 6859–6866
   PubMed Web of Science ®Google Scholar
• Song H., Nieto G. R., Perez D. R. A new generation of modified live-attenuated avian influenza viruses using a two-strategy combination as potential vaccine candidates. J Virol 2007; 81: 9238–9248
   Google Scholar
• Wang X., Li M., Zheng H., Muster T., Palese P., Beg A. A., García-Sastre A. Influenza A virus NS1 protein prevents activation of NF-kappaB and induction of alpha/beta interferon. J Virol 2000; 74: 11566–11573
   PubMed Web of Science ®Google Scholar
• Donelan N., Basler C. F., García-Sastre A. A recombinant influenza A virus expressing an RNA-binding-defective NS1 protein induces high levels of beta interferon and is attenuated in mice. J Virol. 2003; 77: 13257–13266
   Google Scholar
• Egorov A., Brandt S., Sereinig S., Romanova J., Ferko B., Katinger D., Grassauer A., Alexandrova G., Katinger H., Muster T. Transfectant influenza A viruses with long deletions in the NS1 protein grow efficiently in Vero cells. J Virol. 1998; 72: 6437–6441
   PubMed Web of Science ®Google Scholar
• Talon J., Salvatore M., O'Neill R. E., Nakaya Y., Zheng H., Muster T., Garcia-Sastre A., Palese P. Influenza A and B viruses expressing altered NS1 proteins: A vaccine approach. Proc. Natl. Acad. Sci. USA 2000; 97: 4309–4314
   PubMed Web of Science ®Google Scholar
• Garcia-Sastre A., Egorov A., Matassov D., Brandt S., Levy D. E., Durbin J. E., Palese P., Muster T. Influenza A virus lacking the NS1 gene replicates in interferon-deficient systems. Virology. 1998; 252: 324–330
   PubMed Web of Science ®Google Scholar
• Quinlivan M., Zamarin D., García-Sastre A., Cullinane A., Chambers T., Palese P. Attenuation of equine influenza viruses through truncations of the NS1 protein. J Virol. 2005; 79: 8431–8439
   PubMed Web of Science ®Google Scholar
• Ferko B., Stasakova J., Romanova J., Kittel C., Sereinig S., Katinger H., Egorov A. Immunogenicity and protection efficacy of replication-deficient influenza A viruses with altered NS1 genes. J Virol. 2004; 78: 13037–13045
   PubMed Web of Science ®Google Scholar
• Proietti E., Bracci L., Puzelli S., Di. Pucchio T., Sestili P., De. Vincenzi E., Venditti M., Capone I., Seif I., De. Maeyer E., Tough D., Donatelli I., Belardelli F. Type I IFN as a natural adjuvant for a protective immune response: lessons from the influenza vaccine model. J Immunol. 2002; 169: 375–383
   PubMed Web of Science ®Google Scholar
• Richt J. A., Lekcharoensuk P., Lager K. M., Vincent A. L., Loiacono C. M., Janke B. H., Wu W. H., Yoon K. J., Webby R. J., Solórzano A., García-Sastre A. Vaccination of pigs against swine influenza viruses by using an NS1-truncated modified live-virus vaccine. J Virol 2006; 80: 11009–11018
   PubMedGoogle Scholar
• Vincent A. L., Ma W., Lager K. M., Janke B. H., Webby R. J., García-Sastre A., Richt J. A. Efficacy of intranasal administration of a truncated NS1 modified live influenza virus vaccine in swine. Vaccine 2007; 25: 7999–8009
   PubMed Web of Science ®Google Scholar
• Watanabe T., Watanabe S., Ito H., Kida H., Kawaoka Y. Influenza A virus can undergo multiple cycles of replication without M2 ion channel activity. J Virol 2001; 75: 5656–5662
   Google Scholar
• Takeda M., Pekosz A., Shuck K., Pinto L. H., Lamb R. A. Influenza a virus M2 ion channel activity is essential for efficient replication in tissue culture. J Virol 2002; 76: 1391–1399
   PubMed Web of Science ®Google Scholar
• Iwatsuki-Horimoto K., Horimoto T., Noda T., Kiso M., Maeda J., Watanabe S., Muramoto Y., Fujii K., Kawaoka Y. The cytoplasmic tail of the influenza A virus M2 protein plays a role in viral assembly. J Virol 2006; 80: 5233–5240
   PubMedGoogle Scholar
• McCown M. F., Pekosz A. The influenza A virus M2 cytoplasmic tail is required for infectious virus production and efficient genome packaging. J Virol 2005; 79: 3595–3605
   PubMedGoogle Scholar
• McCown M. F., Pekosz A. Distinct domains of the influenza a virus M2 protein cytoplasmic tail mediate binding to the M1 protein and facilitate infectious virus production. J Virol 2006; 80: 3595–3605
   Google Scholar
• Watanabe T., Watanabe S., Kida H., Kawaoka Y. Influenza A virus with defective M2 ion channel activity as a live vaccine. Virology 2002; 299: 266–270
   PubMed Web of Science ®Google Scholar
• Watanabe T., Watanabe S., Kim J. H., Hatta M., Kawaoka Y. Novel approach to the development of effective H5N1 influenza A virus vaccines: use of M2 cytoplasmic tail mutants. J Virol 2008; 82: 2486–2492
   PubMed Web of Science ®Google Scholar
• Wolff J. A., Malone R. W., Williams P., Chong W., Acsadi G., Jani A., Felgner P. L. Direct gene transfer into mouse muscle in vivo. Science. 1990; 247: 1465–1468
   PubMed Web of Science ®Google Scholar
• Ulmer J. B., Donnelly J. J., Parker S. E., Rhodes G. H., Felgner P. L., Dwarki V. J., Gromkowski S. H., Deck R. R., DeWitt C. M., Friedman A., Hawe L. A., Leander K. R., Martinez D., Perry H. C., Shiver J. W., Montgomery D. L., Liu M. A. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science. 1993; 259: 1745–1749
   PubMed Web of Science ®Google Scholar
• Ulmer J. B., Fu T. M., Deck R. R., Friedman A., Guan L., DeWitt C., Liu X., Wang S., Liu M. A., Donnelly J. J., Caulfield M. J. Protective CD4+ and CD8+ T cells against influenza virus induced by vaccination with nucleoprotein DNA. J Virol 1998; 72: 5648–5653
   PubMed Web of Science ®Google Scholar
• Robinson H. L., Hunt L. A., Webster R. G. Protection against a lethal influenza virus challenge by immunization with a haemagglutinin-expressing plasmid DNA. Vaccine 1993; 11: 957–960
   PubMed Web of Science ®Google Scholar
• Donnelly J. J., Friedman A., Martinez D., Montgomery D. L., Shiver J. W., Motzel S. L., Ulmer J. B., Liu M. A. Preclinical efficacy of a prototype DNA vaccine: enhanced protection against antigenic drift in influenza virus. Nat. Med. 1995; 1: 583–587
   PubMed Web of Science ®Google Scholar
• Epstein S., Stack A., Misplon J. A., Lo C. Y., Mostowski H., Bennink J., Subbarao K. Vaccination with DNA encoding internal proteins of influenza virus does not require CD8(+) cytotoxic T lymphocytes: either CD4(+) or CD8(+) T cells can promote survival and recovery after challenge. Int. Immunol. 2000; 12: 91–101
   PubMed Web of Science ®Google Scholar
• Fu T. M., Guan L., Friedman A., Schofield T. L., Ulmer J. B., Liu M. A., Donnelly J. J. Dose dependence of CTL precursor frequency induced by a DNA vaccine and correlation with protective immunity against influenza virus challenge. J Immunol. 1999; 162: 4163–4170
   PubMed Web of Science ®Google Scholar
• Ljungberg K., Wahren B., Almqvist J., Hinkula J., Linde A., Winberg G. Effective construction of DNA vaccines against variable influenza genes by homologous recombination. Virology 2000; 268: 244–250
   Google Scholar
• Epstein S., Kong W. P., Misplon J. A., Lo C. Y., Tumpey T. M., Xu L., Nabel G. J. Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine. 2005; 23: 5404–5410
   PubMed Web of Science ®Google Scholar
• Liu M. A., McClements W., Ulmer J. B., Shiver J., Donnelly J. Immunization of non-human primates with DNA vaccines. Vaccine. 1997; 15: 909–912
   PubMed Web of Science ®Google Scholar
• Robinson H. L., Boyle C. A., Feltquate D. M., Morin M. J., Santoro J. C., Webster R. G. DNA immunization for influenza virus: studies using hemagglutinin- and nucleoprotein-expressing DNAs. J Infect Dis 1997; 176: S50–S55
   PubMedGoogle Scholar
• Kodihalli S., Goto H., Kobasa D. L., Krauss S., Kawaoka Y., Webster R. G. DNA vaccine encoding hemagglutinin provides protective immunity against H5N1 influenza virus infection in mice. J. Virol. 1999; 73: 2094–2098
   PubMed Web of Science ®Google Scholar
• Chen Z., Yoshikawa T., Kadowaki S., Hagiwara Y., Matsuo K., Asanuma H., Aizawa C., Kurata T., Tamura S. Protection and antibody responses in different strains of mouse immunized with plasmid DNAs encoding influenza virus haemagglutinin, neuraminidase and nucleoprotein. J. Gen. Virol. 1999; 80: 2559–2564
   PubMed Web of Science ®Google Scholar
• Chen Z., Matsuo K., Asanuma H., Takahashi H., Iwasaki T., Suzuki Y., Aizawa C., Kurata T., Tamura S. Enhanced protection against a lethal influenza virus challenge by immunization with both hemagglutinin- and neuraminidase-expressing DNAs. Vaccine. 1999; 17: 653–659
   PubMed Web of Science ®Google Scholar
• Epstein S., Tumpey T. M., Misplon J. A., Lo C. Y., Cooper L. A., Subbarao K., Renshaw M., Sambhara S., Katz J. M. DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice. Emerg. Infect. Dis. 2002; 8: 796–801
   PubMed Web of Science ®Google Scholar
• Wang S., Taaffe J., Parker C., Solorzano A., Cao H., Garcia-Sastre A., Lu S. Hemagglutinin (HA) proteins from H1 and H3 serotypes of influenza A viruses require different antigen designs for the induction of optimal protective antibody responses as studied by codon-optimized HA DNA vaccines. J Virol 2006; 80: 11628–11637
   Web of Science ®Google Scholar
• Jiang Y., Yu K., Zhang H., Zhang P., Li C., Tian G., Li Y., Wang X., Ge J., Bu Z., Chen H. Enhanced protective efficacy of H5 subtype avian influenza DNA vaccine with codon optimized HA gene in a pCAGGS plasmid vector. Antviral Res. 2007; 75: 234–241
   PubMed Web of Science ®Google Scholar
• Jimenez G. S., Planchon R., Wei Q., Rusalov D., Geall A., Enas J., Lalor P., Leamy V., Vahle R., Luke C. J., Rolland A., Kaslow D. C., Smith L. R. Vaxfectin-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge. Hum. Vaccin. 2007; 3: 157–164
   PubMed Web of Science ®Google Scholar
• Ohba K., Yoshida S., Zahidunnabi D. M., Shimura H., Sakamaki N., Takeshita F., Yamamoto N., Okuda K. Mutant influenza A virus nucleoprotein is preferentially localized in the cytoplasm and its immunization in mice shows higher immunogenicity and cross-reactivity. Vaccine 2007; 25: 4291–4300
   Google Scholar
• Tompkins S., Zhao Z. S., Lo C. Y., Misplon J. A., Liu T., Ye Z., Hogan R. J., Wu Z., Benton K. A., Tumpey T. M., Epstein S. L. Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg. Infect. Dis. 2007; 13: 426–435
   PubMed Web of Science ®Google Scholar
• Draghia-Akli R., Khan A. S., Brown P. A., Pope M. A., Wu L., Hirao L., Weiner D. B. Parameters for DNA vaccination using adaptive constant-current electroporation in mouse and pig models. Vaccine 2008; 26
   Google Scholar
• Khan A. S., Pope M. A., Draghia-Akli R. Highly efficient constant-current electroporation increases in vivo plasmid expression. DNA Cell Biol. 2005; 24: 810–818
   PubMed Web of Science ®Google Scholar
• Tjelle T. E., Rabussay D., Ottensmeier C., Mathiesen I., Kjeken R. Taking electroporation-based delivery of DNA vaccination into humans: a generic clinical protocol. Methods Mol. Biol. 2008; 423: 497–507
   PubMedGoogle Scholar
• Jean Patterson L., Peng B., Nan X., Robert-Guroff M. Live adenovirus recombinants as vaccine vectors. New Generation Vaccines, M. Levine, J. B. Kaper, R. Rappuoli, M. A. Liu, M. F. Good. Marcel Dekker, New York, Basel 2004; 325–336
   Google Scholar
• Lo C. Y., Wu Z., Misplon J. A., Price G. E., Pappas C., Kong W. P., Tumpey T. M., Epstein S. L. Comparison of vaccines for induction of heterosubtypic immunity to influenza A virus: cold-adapted vaccine versus DNA prime-adenovirus boost strategies. Vaccine. 2008; 26: 2062–2072
   PubMed Web of Science ®Google Scholar
• Hoelscher M., Garg S., Bangari D. S., Belser J. A., Lu X., Stephenson I., Bright R. A., Katz J. M., Mittal S. K., Sambhara S. Development of adenoviral-vector-based pandemic influenza vaccine against antigenically distinct human H5N1 strains in mice. Lancet. 2006; 367: 475–481
   PubMed Web of Science ®Google Scholar
• Gao W., Soloff A. C., Lu X., Montecalvo A., Nguyen D. C., Matsuoka Y., Robbins P. D., Swayne D. E., Donis R. O., Katz J. M., Barratt-Boyes S. M., Gambotto A. Protection of mice and poultry from lethal H5N1 avian influenza virus through adenovirus-based immunization. J Virol 2006; 80: 1959–1964
   PubMed Web of Science ®Google Scholar
• Wesley R., Tang M., Lager K. M. Protection of weaned pigs by vaccination with human adenovirus 5 recombinant viruses expressing the hemagglutinin and the nucleoprotein of H3N2 swine influenza virus. Vaccine. 2004; 22: 3427–3434
   PubMed Web of Science ®Google Scholar
• Roy S., Kobinger G. P., Lin J., Figueredo J., Calcedo R., Kobasa D., Wilson J. M. Partial protection against H5N1 influenza in mice with a single dose of a chimpanzee adenovirus vector expressing nucleoprotein. Vaccine. 2007; 25: 6845–6851
   PubMed Web of Science ®Google Scholar
• HIV vaccine failure prompts Merck to halt trial. Nature. 2007; 449: 390
   PubMed Web of Science ®Google Scholar
• Failed HIV vaccine may have increased vulnerability to infection. Clin Infect Dis 2008; 46: iii
   Google Scholar
• Sekaly R. P. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?. J. Exp. Med. 2008; 205: 7–12
   PubMed Web of Science ®Google Scholar
• Karaca K., Swayne D. E., Grosenbaugh D., Bublot M., Robles A., Spackman E., Nordgren R. Immunogenicity of fowlpox virus expressing the avian influenza virus H5 gene (TROVAC AIV-H5) in cats. Clin Diagn Lab Immunol 2005; 12: 1340–1342
   PubMedGoogle Scholar
• Veits J., Wiesner D., Fuchs W., Hoffmann B., Granzow H., Starick E., Mundt E., Schirrmeier H., Mebatsion T., Mettenleiter T. C., Romer-Oberdorfer A. Newcastle disease virus expressing H5 hemagglutinin gene protects chickens against Newcastle disease and avian influenza. Proc Natl Acad Sci USA 2006; 103: 8197–8202
   PubMed Web of Science ®Google Scholar
• Sylte M. J., Hubby B., Suarez D. L. Influenza neuraminidase antibodies provide partial protection for chickens against high pathogenic avian influenza infection. Vaccine 2007; 25: 3763–3772
   PubMed Web of Science ®Google Scholar
• Hubby B., Talarico T., Maughan M., Reap E. A., Berglund P., Kamrud K. I., Copp L., Lewis W., Cecil C., Norberg P., Wagner J., Watson A., Negri S., Burnett B. K., Graham A., Smith J. F., Chulay J. D. Development and preclinical evaluation of an alphavirus replicon vaccine for influenza. Vaccine 2007; 25: 8180–8189
   PubMed Web of Science ®Google Scholar
• Neirynck S., Deroo T., Saelens X., Vanlandschoot P., Jou W. M., Fiers W. A universal influenza A vaccine based on the extracellular domain of the M2 protein. Nat. Med. 1999; 5: 1157–1163
   PubMed Web of Science ®Google Scholar
• Fiers W., De Filette M., Birkett A., Neirynck S., Min Jou W. A “universal” human influenza A vaccine. Virus Research 2004; 103: 173–176
   PubMed Web of Science ®Google Scholar
• De Filette M., Min Jou W., Birkett A., Lyons K., Schultz B., Tonkyro A., Resch S., Fiers W. Universal influenza A vaccine: optimization of M2-based constructs. Virology. 2005; 337: 149–161
   PubMed Web of Science ®Google Scholar
• De Filette M., Fiers W., Martens W., Birkett A., Ramne A., Lowenadler B., Lycke N., Jou W. M., Saelens X. Improved design and intranasal delivery of an M2e-based human influenza A vaccine. Vaccine 2006; 24: 6597–6601
   PubMedGoogle Scholar
• Zou P., Liu W., Chen Y. H. The epitope recognized by a monoclonal antibody in influenza A virus M2 protein is immunogenic and confers immune protection. Int. Immunopharmacol. 2005; 5: 631–635
   PubMed Web of Science ®Google Scholar
• Fan J., Liang X., Horton M. S., Perry H. C., Citron M. P., Heidecker G. J., Fu T. M., Joyce J., Przysiecki C. T., Keller P. M., Garsky V. M., Ionescu R., Rippeon Y., Shi L., Chastain M. A., Condra J. H., Davies M. E., Liao J., Emini E. A., Shiver J. W. Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. Vaccine 2004; 22: 2993–3003
   PubMed Web of Science ®Google Scholar
• Jegerlehner A., Schmitz N., Storni T., Bachmann M. F. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J. Immunol. 2004; 172: 5598–5605
   PubMed Web of Science ®Google Scholar
• Slepushkin V. A., Katz J. M., Black R. A., Gamble W. C., Rota P. A., Cox N. J. Protection of mice against influenza A virus challenge by vaccination with baculovirus-expressed M2 protein. Vaccine 1995; 13: 1399–1402
   PubMed Web of Science ®Google Scholar
• Ernst W. A., Kim H. J., Tumpey T. M., Jansen A. D., Tai W., Cramer D. V., Adler-Moore J. P., Fujii G. Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines. Vaccine 2006; 24: 5158–5168
   PubMed Web of Science ®Google Scholar
• Huleatt J. W., Nakaar V., Desai P., Huang Y., Hewitt D., Jacobs A., Tang J., McDonald W., Song L., Evans R. K., Umlauf S., Tussey L., Powell T. J. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 2008; 26: 201–214
   PubMed Web of Science ®Google Scholar
• Frace A. M., Klimov A. I., Rowe T., Black R. A., Katz J. M. Modified M2 proteins produce heterotypic immunity against influenza A virus. Vaccine 1999; 17: 2237–2244
   PubMed Web of Science ®Google Scholar
• Ilyinskii P., Gabai V. L., Sunyaev S. R., Thoidis G., Shneider A. M. Toxicity of Influenza A Virus Matrix Protein 2 for Mammalian Cells is Associated with its Intrinsic Proton-Channeling Activity. Cell Cycle. 2007; 6: 2043–2047
   PubMed Web of Science ®Google Scholar
• Saha S., Yoshida S., Ohba K., Matsui K., Matsuda T., Takeshita F., Umeda K., Tamura Y., Okuda K., Klinman D., Xin K. Q., Okuda K. A fused gene of nucleoprotein (NP) and herpes simplex virus genes (VP22) induces highly protective immunity against different subtypes of influenza virus. Virology. 2006; 354: 48–57
   PubMed Web of Science ®Google Scholar
• Wong S. B., Buck C. B. J., Shen X., Siliciano R. F. An evaluation of enforced rapid proteasomal degradation as a means of enhancing vaccine-induced CTL responses. J. Immunol. 2004; 173: 3073–3083
   Google Scholar
• Altstein A. D., Gitelman A. K., Smirnov Y. A., Piskareva L. M., Zakharova L. G., Pashvykina G. V., Shmarov M. M., Zhirnov O. P., Varich N. P., Ilyinskii P. O., Shneider A. M. Immunization with influenza A NP-expressing vaccinia virus recombinant protects mice against experimental infection with human and avian influenza viruses. Arch. Virol. 2006; 151: 921–931
   PubMed Web of Science ®Google Scholar
• Ilyinskii P. O., Meriin A. B., Gabai V. L., Zhirnov O. P., Thoidis G., Shneider A. M. Prime-boost vaccination with a combination of proteosome-degradable and wild-type forms of two influenza proteins leads to augmented CTL response. Vaccine 2008; 26: 2177–2185
   Google Scholar
• Chen Z., Sahashi Y., Matsuo K., Asanuma H., Takahashi H., Iwasaki T., Suzuki Y., Aizawa C., Kurata T., Tamura S. Comparison of the ability of viral protein-expressing plasmid DNAs to protect against influenza. Vaccine 1998; 16: 1544–1549
   PubMed Web of Science ®Google Scholar
• Doherty P. C., Turner S. J., Webby R. G., Thomas P. G. Influenza and the challenge for immunology. Nat Immunol 2006; 7: 449–455
   PubMed Web of Science ®Google Scholar